-
Views
-
Cite
Cite
Vanaporn Wuthiekanun, Allen C. Cheng, Wirongrong Chierakul, Premjit Amornchai, Direk Limmathurotsakul, Wipada Chaowagul, Andrew J. H. Simpson, Jennifer M. Short, Gumphol Wongsuvan, Bina Maharjan, Nicholas J. White, Sharon J. Peacock, Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei, Journal of Antimicrobial Chemotherapy, Volume 55, Issue 6, June 2005, Pages 1029–1031, https://doi.org/10.1093/jac/dki151
- Share Icon Share
Abstract
Objectives: Trimethoprim/sulfamethoxazole is commonly used to treat melioidosis. Antimicrobial susceptibility testing using the disc diffusion method is commonly used in melioidosis-endemic areas, but may overestimate resistance to trimethoprim/sulfamethoxazole.
Patients and methods: We performed disc diffusion and Etest on isolates from the first positive culture for all patients presenting to Sappasithiprasong Hospital, Ubon Ratchathani, Thailand, with culture-confirmed melioidosis between 1992 and 2003.
Results: The estimated resistance rate for 1976 clinical Burkholderia pseudomallei isolates was 13% by Etest and 71% by disc diffusion. All isolates classed as either susceptible (n=358) or as having intermediate resistance (n=218) on disc diffusion were susceptible by Etest. Only 258 of the 1400 (18%) isolates classed as resistant on disc diffusion were resistant by Etest.
Conclusions: Disc diffusion testing of B. pseudomallei may be useful as a limited screening tool in resource poor settings. Isolates assigned as ‘susceptible’ or ‘intermediate’ by disc diffusion may be viewed as ‘susceptible’; those assigned as ‘resistant’ require further evaluation by MIC methodology.